Website intended for a NZ health professional readership
GP Jo Scott-Jones warns that New Zealanders with long COVID may go unrecognised and unsupported due to the current small number of patients affected. Here’s what you need to know to help ensure that doesn’t happen
1. Ministry of Health. COVID-19: Current cases. 17 August 2021. https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-data-and-statistics/covid-19-current-cases
2. Liu B, Jayasundara D, Pye V, et al. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. Lancet Reg Health West Pac 2021;12:100193.
3. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;101019: 15 July online.
4. Centers for Disease Control and Prevention. Post-COVID Conditions. 12 July 2021. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html
5. Editorial. COVID-19 pathophysiology: looking beyond acute disease. Lancet Respir Med 2021;9(6):545.
6. Campbell Murdoch. Can ‘Long COVID’ shine light on Chronic Fatigue Syndrome? 7 December 2020. https://www.nzdoctor.co.nz/article/opinion/can-long-covid-shine-light-chronic-fatigue-syndrome
7. National Health Service. NHS sets up specialist young people’s services in £100 million long COVID care expansion. 15 June 2021. https://www.england.nhs.uk/2021/06/nhs-sets-up-specialist-young-peoples-services-in-100-million-long-covid-care-expansion/
8. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27(4):601–15.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
